We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00838643
Recruitment Status : Unknown
Verified February 2009 by Ospedale Santa Croce-Carle Cuneo.
Recruitment status was:  Active, not recruiting
First Posted : February 6, 2009
Last Update Posted : February 9, 2009
Sponsor:
Information provided by:
Ospedale Santa Croce-Carle Cuneo

Brief Summary:
Evaluation of incidence of invasive aspergillosis in patients who have undergone an allogeneic stem cell transplantation, with particular regard to the role of galactomannan assay and of early TC scan in asymptomatic patients.

Condition or disease
Hematological Diseases Invasive Aspergillosis

Study Type : Observational
Actual Enrollment : 220 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Incidence of Invasive Aspergillosis in Allogeneic Stem Cell Transplantation Patients: an Italian Prospective Multicentre Study
Study Start Date : May 2002
Primary Completion Date : June 2007
Estimated Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Aspergillosis
U.S. FDA Resources

Group/Cohort
Allogeneic pts
Adult allogeneic HSCT recipients



Primary Outcome Measures :
  1. Incidence of invasive aspergillosis [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Clinical applicability of the EORTC/MSG criteria in a prospective multicenter trial [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult patients given allogeneic HSCT in tertiary care centers or university hospitals in Piedmont
Criteria

Inclusion Criteria:

  • Age > 16 years
  • Allogeneic HSCT for a haematological disease
  • Written informed consent to the study

Exclusion Criteria:

  • Pediatric patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00838643


Locations
Italy
Azienda Sanitaria Ospedaliera santa Croce e Carle
Cuneo, Italy, 12100
Sponsors and Collaborators
Ospedale Santa Croce-Carle Cuneo

Responsible Party: Nicola Mordini, Ospedale Santa Croce-Carle Cuneo
ClinicalTrials.gov Identifier: NCT00838643     History of Changes
Other Study ID Numbers: Gal-01
First Posted: February 6, 2009    Key Record Dates
Last Update Posted: February 9, 2009
Last Verified: February 2009

Keywords provided by Ospedale Santa Croce-Carle Cuneo:
allogeneic transplantation
Invasive aspergillosis

Additional relevant MeSH terms:
Aspergillosis
Hematologic Diseases
Mycoses
Hyalohyphomycosis
Dermatomycoses
Lung Diseases, Fungal
Skin Diseases, Infectious
Skin Diseases